AlphaCentric Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

AlphaCentric Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-26,812	Closed	-$250K	–	265
2025 Q4	$250K	Buy	+26,812	New	+$224K	0.25%	126
2023 Q4	–	Sell	-95,000	Closed	-$1.17M	–	245
2023 Q3	$1.17M	Sell	95,000 -15,000	-14%	-$196K	0.66%	52
2023 Q2	$1.31M	Buy	+110,000	New	+$1.44M	0.73%	52

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

AlphaCentric Advisors's DAWN Position: Q1 2026 in Review

AlphaCentric Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 26,812 shares — an estimated $250K sold.

AlphaCentric Advisors first reported a position in DAWN in Q2 2023 and held it in 3 quarters. The position peaked at $1.31M in Q2 2023. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

AlphaCentric Advisors reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
AlphaCentric Advisors sold 26,812 Day One Biopharmaceuticals shares in Q1 2026, an estimated $250K.
AlphaCentric Advisors first reported a position in Day One Biopharmaceuticals in Q2 2023 and held it in 3 quarters.
AlphaCentric Advisors's Day One Biopharmaceuticals position peaked at $1.31M in Q2 2023.
206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.